Table 2.

Linear regression analysis with log-transformed serum CGRP-LI levels (mol/l) T0

Variable	β (95% CI)1	p	β (95% CI)2	p
Age	0.07 (-0.001–0.13)	0.05	0.07 (0.004–0.14)	0.04
Sex	1.92 (-0.41–4.25)	0.10	2.50 (0.17–4.82)	0.04
Migraine days baseline	0.09 (-0.06–0.24)	0.24	0.11 (-0.04–0.26)	0.14
Serum CGRP-LI	-1.033 (-2.37–0.30)	0.13	-0.80 (-2.16–0.55)	0.24
N = 94. 1Simple linear regression. 2multiple regression, corrected for all tested variables. CI = confidence interval. T0 = baseline, before starting treatment with erenumab. The outcome is absolute reduction migraine days during month 3 after starting treatment with erenumab compared to baseline. One month is defined as 28 days.